Zoetis Inc. $ZTS Shares Sold by KBC Group NV

KBC Group NV lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 11.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 344,903 shares of the company’s stock after selling 46,132 shares during the period. KBC Group NV’s holdings in Zoetis were worth $40,771,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ZTS. Prosperity Bancshares Inc bought a new position in shares of Zoetis in the fourth quarter worth $25,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the fourth quarter valued at $30,000. Root Financial Partners LLC raised its stake in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Elyxium Wealth LLC bought a new stake in shares of Zoetis during the fourth quarter valued at about $32,000. Finally, Global Assets Advisory LLC acquired a new stake in Zoetis in the first quarter worth about $38,000. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ZTS. HSBC decreased their target price on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. UBS Group reduced their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. Citigroup lowered their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, JPMorgan Chase & Co. dropped their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $120.83.

Zoetis Trading Down 0.5%

Shares of ZTS stock opened at $76.17 on Tuesday. The stock has a 50-day simple moving average of $77.32 and a 200 day simple moving average of $105.54. Zoetis Inc. has a fifty-two week low of $71.47 and a fifty-two week high of $160.48. The stock has a market capitalization of $31.93 billion, a P/E ratio of 12.63, a P/E/G ratio of 1.19 and a beta of 0.75. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the firm earned $1.48 earnings per share. Zoetis’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.87 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s payout ratio is currently 35.16%.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis saw unusual options activity, with traders buying 8,095 call options, about 59% above the average daily volume, suggesting some speculative bullish interest.
• Neutral Sentiment: Several law firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter LLP, the Schall Law Firm, Bronstein Gewirtz & Grossman LLC, DJS Law Group, and Bragar Eagel & Squire, reminded investors about a July 27 lead-plaintiff deadline in an existing class action related to Zoetis securities purchased between January 14, 2025 and May 6, 2026. Article Title
• Negative Sentiment: The class-action campaign keeps attention on alleged securities-law violations, which can create legal uncertainty and pressure the stock until the case is resolved. Article Title

Insider Buying and Selling

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frank A. Damelio purchased 6,650 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 11,650 shares of company stock worth $886,384 in the last ninety days. 0.22% of the stock is currently owned by corporate insiders.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.